Clear Search

Showing 2 results for “BLISS” published 2025.

April 2025

Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab

Rheumatol (Oxford), 2025 DOI: 10.1093/rheumatology/keaf215. Epub ahead of print

Depascale et al. used unsupervised machine learning to identify three SLE endotypes based on B cell immunophenotyping and serological profiles. Belimumab was most effective in patients with transitional and naïve B cell enrichment (Cluster 2), where it significantly increased the likelihood of achieving sustained LLDAS and DORIS remission.

more…

March 2025

Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials

Rheumatol, 2025. Epub ahead of print. DOI: 10.1093/rheumatology/keaf145

Grosso et al. conducted a post-hoc analysis of five phase III trials, including 3086 patients, to evaluate the efficacy of belimumab in improving mucocutaneous manifestations of SLE. The results demonstrated that belimumab significantly improved disease activity as measured by the mcBILAG and mcSLEDAI-2K indices compared with placebo and reduced flare rates in patients with high disease activity and serological positivity.

more…